3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Breast Neoplasms
39
Ovarian Neoplasms
32
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Fallopian Tube Neoplasms
16
Neoplasm Metastasis
14
Pancreatic Neoplasms
9
Neoplasms
9
Endometrial Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Small Cell Lung Carcinoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Glioma
6
Stomach Neoplasms
5
Sarcoma
5
Lung Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Metastatic Castration-resistant Prostate Cancer
4
Carcinoma, Ovarian Epithelial
4
Solid Tumors
3
Recurrence
3
Osteosarcoma
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Cholangiocarcinoma
3
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Interventions
Magnetic Resonance Spectroscopy
7
lutetium Lu 177 dotatate
6
Specimen Handling
5
Bevacizumab
4
gallium Ga 68 dotatate
3
abemaciclib
3
Radiosurgery
3
Proton Therapy
3
Nivolumab
3
pembrolizumab
2
Surveys and Questionnaires
2
Sunitinib
2
Protons
2
Observation
2
ONC206
2
Ipilimumab
2
Hydroxyurea
2
Ga(III)-DOTATOC
2
Everolimus
2
Elasticity Imaging Techniques
2
CTLA-4 Antigen
2
ribociclib
1
regorafenib
1
olaparib
1
neratinib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
capivasertib
1
cabozantinib
1
brigatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
olaparib
×
1 year
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled